SARS-CoV-2 entry requires sequential cleavage of the spike glycoprotein at the S1/S2 and
the S2ʹ cleavage sites to mediate membrane fusion. SARS-CoV-2 has a polybasic insertion (…

Since its emergence in 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
has caused hundreds of millions of cases and continues to circulate globally. To establish …

Background Accurate antibody tests are essential to monitor the SARS-CoV-2 pandemic.
Lateral flow immunoassays (LFIAs) can deliver testing at scale. However, reported …

Influenza pandemics occur unpredictably when zoonotic influenza viruses with novel antigenicity
acquire the ability to transmit amongst humans 1 . Host range breaches are limited by …

SARS-CoV-2 enters cells via its spike glycoprotein which must be cleaved sequentially at the
S1/S2, then the S2’ cleavage sites (CS) to mediate membrane fusion. SARS-CoV-2 has a …

Objective To evaluate the performance of new lateral flow immunoassays (LFIAs) suitable
for use in a national coronavirus disease 2019 (covid-19) seroprevalence programme (real …

Lineage B.1.1.7 (Variant of Concern 202012/01) is a new SARS-CoV-2 variant which was
first sequenced in the UK in September 2020 before becoming the majority strain in the UK …

SARS-CoV-2 has a broad mammalian species tropism infecting humans, cats, dogs, and
farmed mink. Since the start of the 2019 pandemic, several reverse zoonotic outbreaks of SARS…

Children are less likely than adults to suffer severe symptoms when infected with severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while influenza A H1N1 severity is …

Human ANP32A and ANP32B are essential but redundant host factors for influenza virus
genome replication. While most influenza viruses cannot replicate in edited human cells …